J.M. Smucker Company (The) vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Orrville OH consumer foods (NYSE: SJM) at $8.7B FY2025 revenue (+7%); Uncrustables fastest-growing brand, Hostess ($5.6B acquisition 2023) integration challenge, Jif/Folgers/Café Bustelo portfolio competing with Kraft Heinz.
About
The J.M. Smucker Company is an Orrville, Ohio-based consumer packaged goods company — publicly traded on the New York Stock Exchange (NYSE: SJM) as an S&P 500 Consumer Staples component — manufacturing and marketing a portfolio of leading food and beverage brands across coffee, peanut butter, fruit spreads, frozen sandwiches, and sweet baked goods through approximately 8,500 employees, with fiscal year 2025 net sales of $8.7 billion (+7% year-over-year). J.M. Smucker's brand portfolio spans three segments: U.S. Retail Pet Foods (Milk-Bone dog treats, Meow Mix, 9Lives, Kibbles 'n Bits), U.S. Retail Coffee (Folgers, Café Bustelo, Dunkin' retail coffee), and U.S. Retail Consumer Foods (Smucker's jams and jellies, Jif peanut butter, Uncrustables frozen sandwiches, and the Hostess sweet baked snacks portfolio). The Hostess acquisition (November 2023, $5.6 billion) made Smucker the owner of America's most iconic sweet baked goods brands — Twinkies, Donettes, Ding Dongs, Ho Hos, and Hostess CupCakes — while presenting integration challenges as the sweet baked snacks category faces shelf-stable competition from private label and shifting consumer preferences. CEO Mark Smucker (grandson of founder Jerome Monroe Smucker who founded the company in 1897) leads the company's brand portfolio management strategy, with Uncrustables (frozen peanut butter and jelly sandwiches, the fastest-growing Smucker brand) and Café Bustelo (Spanish-language espresso-style coffee, growing with US Hispanic demographics) as the primary growth drivers.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.